



## Caribou Biosciences to Present at Upcoming Investor Conference

May 3, 2022

BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](https://www.cariboubio.com) (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat at the following upcoming investor conference in May:

- **BofA Securities 2022 Healthcare Conference**

Tuesday, May 10<sup>th</sup>, at 8:00 am PT

A webcast of the fireside chat presentation will be accessible via Caribou's website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event.

### **About Caribou's Novel Next-Generation CRISPR Platform**

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNA; pronounced "chardonnays" that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

### **About Caribou Biosciences, Inc.**

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.

Follow us @CaribouBio and visit [www.cariboubio.com](https://www.cariboubio.com).

*"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.*

### **Caribou Biosciences, Inc.**

#### **Contacts:**

Amy Figueroa, CFA  
Investor Relations and Corporate  
Communications  
[afigueroa@cariboubio.com](mailto:afigueroa@cariboubio.com)

#### **Investors and Media:**

Elizabeth Wolffe, Ph.D., and Sylvia Wheeler  
Wheelhouse LSA  
lwolffe@wheelhousesa.com  
[swheeler@wheelhousesa.com](mailto:swheeler@wheelhousesa.com)